Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 1,207 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Study Powder Clear all
Completed Phase 2 Interventional Results available

Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders

NCT00551200
View directory record Official record
Conditions
Urea Cycle Disorders
Interventions
HPN-100, BUPHENYL®
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Early Phase 1 Interventional

Effect of a High Citrate Beverage on Urine Chemistry in Urinary Stone Disease

NCT04697706
View directory record Official record
Conditions
Urinary Stone
Interventions
Moonstone, Water
Dietary Supplement · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Pharmacodynamics and Pharmacokinetics of Acetylsalicylic Acid Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Healthy Adults.

NCT05625334
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ASA, non-enteric-coated chewable aspirin
Drug
Lead sponsor
Vectura, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 22, 2024 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TA-65 Pharmacokinetic Study

NCT02731807
View directory record Official record
Conditions
Healthy
Interventions
Dose A: TA-65 24mg, powder, Dose B: TA-65, 8mg, powder, Dose C: TA-65 3.2mg, capsule, Dose D: TA-65 8mg, capsule, Dose E: TA-65 32mg, capsule
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
22 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 9, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Terminated Phase 2 Interventional Results available

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

NCT04056299
View directory record Official record
Conditions
Hen Egg Allergy
Interventions
AR201 powder, Placebo powder
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
11
States / cities
Little Rock, Arkansas • Rolling Hills Estates, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

NCT05918822
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 3 Interventional

A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes

NCT00330473
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Insulin Inhalation Powder, Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Huntington Beach, California • Pomona, California • Jacksonville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

NCT01453023
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone Furoate, Fluticasone Furoate/Vilanterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
5 Years to 11 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Huntington Beach, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

NCT01157117
View directory record Official record
Conditions
Milk Allergy
Interventions
Placebo for omalizumab, Omalizumab, Milk powder
Biological · Drug
Lead sponsor
Hugh A Sampson, MD
Other
Eligibility
7 Years to 35 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
3
States / cities
Stanford, California • Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2020 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 3 Interventional

Insulin Clamp Ancillary Study for Assessment of Insulin Resistance

NCT02045290
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Metformin, Placebo
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
12 Years to 19 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

NCT04660890
View directory record Official record
Conditions
Healthy
Interventions
ALXN2050, ALXN2050-matching Placebo, Moxifloxacin, Moxifloxacin-matching Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 30, 2026, 12:24 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Methylation Diet and Lifestyle Study

NCT03472820
View directory record Official record
Conditions
Lifestyle, Diet, Healthy
Interventions
Diet Recommendations, Lifestyle Recommendations, Exercise Recommendations, Stress Management Recommendations, PhytoGanix (tropical fruit flavor), UltraFlora Intensive Care
Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
50 Years to 72 Years · Male only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy

NCT01645280
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DAS181 Single Dose Escalation Study in Healthy Adults

NCT00876161
View directory record Official record
Conditions
Healthy
Interventions
DAS181, Lactose
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 30, 2026, 12:24 PM EDT
Terminated Phase 1Phase 2 Interventional

Dose Escalation and Expansion Study of SAR444200-based Regimen in Adult Participants With Advanced Solid Tumors

NCT05450562
View directory record Official record
Conditions
Neoplasm
Interventions
SAR444200, Atezolizumab
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Providence, Rhode Island + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 30, 2026, 12:24 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Study of Changes in Total Cholesterol Levels as a Function of Consuming a Supplement Designed to Improve Cardiovascular Health

NCT01890889
View directory record Official record
Conditions
Cholesterol, Hyperlipidemia, Hypercholesteremia
Interventions
Ad-Chol-Pre, Half-dose Ad-Chol-Pre, Defatted egg yolk without the active ingredient of the other two interventions
Dietary Supplement · Other
Lead sponsor
Integrative Health Technologies, Inc.
Network
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 4 Interventional Results available

Impact of Timing on the Efficacy of Zegerid 40 mg in Healing Reflux Esophagitis: A Pilot Study

NCT00693225
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Omeprazole/sodium bicarbonate
Drug
Lead sponsor
Yvonne Romero
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2012 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 1 Interventional

A Phase 1b Study to Assess the Safety and Anti-inflammatory Effects of Two Different Doses of SRT2104 in Patients With Ulcerative Colitis

NCT01453491
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
SRT2104
Drug
Lead sponsor
Sirtris, a GSK Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
13
States / cities
Anaheim, California • Bristol, Connecticut • Owensboro, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 3 Interventional Results available

A 12-week Study to Compare the Efficacy and Safety of Albuterol Spiromax® Versus a Placebo in People 12 Years and Older With Persistent Asthma

NCT01424813
View directory record Official record
Conditions
Asthma
Interventions
Placebo MDPI, Albuterol MDPI
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Costa Mesa, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects

NCT01848340
View directory record Official record
Conditions
HIV-associated Lipodystrophy Syndrome
Interventions
GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty

NCT05422378
View directory record Official record
Conditions
Abdominal Obesity
Interventions
STP705
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Aventura, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study for Fluticasone Propionate and Salmeterol Xinafoate

NCT02649478
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone / Salmeterol, Placebo, Advair Diskus 100/50
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
12 Years and older
Enrollment
1,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
100
States / cities
Glendale, Arizona • Phoenix, Arizona • Surprise, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Early Phase 1 Interventional Results available

Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients

NCT05081583
View directory record Official record
Conditions
Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
Interventions
Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis)
Drug · Dietary Supplement
Lead sponsor
Washington State University
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 30, 2026, 12:24 PM EDT
Completed Not applicable Interventional

Effect of High-Dose Guarana And Cancer-Related Fatigue

NCT03897556
View directory record Official record
Conditions
Cancer-related Fatigue
Interventions
Guarana herb, Usual Care
Dietary Supplement · Other
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Oct 30, 2026, 12:24 PM EDT